Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
04 January 2021 | Story Nonsindiso Qwabe | Photo Anja Aucamp
Dr Sekanse Ntsala

Lecturer in the School of Social Sciences and Language Education at the University of Free State, Dr Sekanse Ntsala, collaborated with colleagues from eight universities across South Africa to produce instructional reading strategies for Sesotho and isiZulu students in the Faculty of Education.

The project will see Dr Ntsala partner in the production of learning material in Sesotho and IsiZulu for Foundation and Intermediate phase lecturers, academics, and students. The project is centred in the Centre for African Language Teaching at the University of Johannesburg. 

Designing African language material is a progressive move 

He said there was a gap in the learning material currently being produced, as it was all produced in English, even for African languages. 

"The dilemma is that thus far, all the material that we use for teaching has been written in English. This means that lecturers have to rely on material written in English, and in some instances, they have to translate into the relevant African language. The challenge with translation is that the final product does not always come out the same. You find that even when lecturers have to compile study guides, they still have to rely on the same material. It's a challenge that affects even students themselves, as discussions and assessments have to be done in the African language in question."

He said rather than to translate the content that has been written in English, the collaboration will result in newly created material for Sesotho and IsiZulu.

The two languages were selected as pilot languages; Dr Ntsala said the aim of the project is to expand the creation of material to other languages in order to eliminate English as the main focus in teaching.

"The main rationale is that it's only fair that we have material that will be relevant to a particular language. The manner in which it is happening now is sort of degrading to other languages," he said.

Dr Ntsala said the material would be completed by the end of 2020 and would then go through the process of getting approval from the deaneries of the approved universities, as well as from the Department of Education.

"We are trying to ensure that every language gets recognition in classrooms. Having material that is language-specific is a step in the right direction to ensure that each language is given the respect it deserves."

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept